Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

8.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
8.1K
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

33
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
33
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Drug Discovery: Overview01:26

Drug Discovery: Overview

9.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
9.5K
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

2.4K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[ATM/H2AX and repair of sperm-DNA damage during cryopreservation].

Zhonghua nan ke xue = National journal of andrology·2011
Same author

Predicting accident frequency at their severity levels and its application in site ranking using a two-stage mixed multivariate model.

Accident; analysis and prevention·2011
Same author

Photothermally enhanced photodynamic therapy delivered by nano-graphene oxide.

ACS nano·2011
Same author

[Characteristics of soil respiration in Phyllostachys edulis forest in Wanmulin Natural Reserve and related affecting factors].

Ying yong sheng tai xue bao = The journal of applied ecology·2011
Same author

Quality changes in sea urchin (Strongylocentrotus nudus) during storage in artificial seawater saturated with oxygen, nitrogen and air.

Journal of the science of food and agriculture·2011
Same author

Global effect of an RNA polymerase β-subunit mutation on gene expression in the radiation-resistant bacterium Deinococcus radiodurans.

Science China. Life sciences·2011

Related Experiment Video

Updated: Oct 16, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.7K

VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives.

Chao Wang1, Yujing Zhang2, Jie Wang1

  • 1The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao Cancer Institute, Qingdao, 266071, Shandong, China.

European Journal of Medicinal Chemistry
|October 17, 2021
PubMed
Summary

Proteolysis targeting chimeras (PROTACs) offer a new way to degrade proteins, even difficult ones. VHL-based PROTACs show promise for treating diseases resistant to traditional therapies.

Keywords:
DegradationPROTACsPromising treatmentUbiquitinationVHL

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.8K

Related Experiment Videos

Last Updated: Oct 16, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.7K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.8K

Area of Science:

  • Biochemistry
  • Medicinal Chemistry
  • Drug Discovery

Background:

  • Proteolysis targeting chimeras (PROTACs) leverage the ubiquitin-proteasome system for targeted protein degradation.
  • PROTACs are emerging as powerful biological tools and potential therapeutics.
  • VHL-based PROTACs are particularly effective for degrading challenging targets like transcription factors.

Purpose of the Study:

  • To review recent advancements in VHL-based PROTACs.
  • To highlight the potential and challenges of VHL-based PROTAC technology.
  • To discuss applications in treating diseases resistant to conventional therapies.

Main Methods:

  • Literature review of VHL-based PROTAC development.
  • Analysis of PROTAC mechanisms targeting specific proteins.
  • Summary of clinical potential and limitations.

Main Results:

  • A wide array of small molecule PROTACs have been developed.
  • VHL-based PROTACs demonstrate efficacy against previously undruggable targets.
  • These PROTACs offer new therapeutic avenues for difficult-to-treat diseases.

Conclusions:

  • VHL-based PROTACs represent a significant breakthrough in targeted protein degradation.
  • This technology holds promise for overcoming limitations of conventional treatments.
  • Further research is needed to address associated challenges and fully realize clinical potential.